MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
MiNK Therapeutics (Nasdaq: INKT) has appointed Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb brings extensive expertise in trauma and critical care medicine, having served 23 years in the U.S. Army and authored over 780 peer-reviewed publications.
Dr. Holcomb joins alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, strengthening MiNK's leadership as it develops invariant natural killer T (iNKT) cell therapies for immune-mediated diseases, pulmonary disorders, and global health security challenges. His expertise in trauma medicine, immune activation, and clinical trial execution will be valuable as MiNK advances its therapeutic programs into late-stage development.
MiNK Therapeutics (Nasdaq: INKT) ha nominato al suo Consiglio di Amministrazione il Colonnello (ritirato) John B. Holcomb, MD, FACS. Il Dr. Holcomb porta una vasta esperienza in trauma e medicina intensiva, avendo servito per 23 anni nell’Esercito degli Stati Uniti e pubblicato oltre 780 articoli sottoposti a revisione paritaria.
Il Dr. Holcomb si aggiunge al recentemente nominato esperto di terapia intensiva polmonare Dr. Terese Hammond, rafforzando la leadership di MiNK mentre sviluppa terapie con cellule T killer naturali invarianti (iNKT) per malattie immunomediate, disturbi polmonari e sfide di salute globale. La sua esperienza in medicina traumatologica, attivazione immunitaria e conduzione di studi clinici sarà preziosa mentre MiNK avanza i propri programmi terapeutici verso la fase avanzata di sviluppo.
MiNK Therapeutics (Nasdaq: INKT) ha nombrado a su Junta Directiva al Coronel (ret.) John B. Holcomb, MD, FACS. El Dr. Holcomb aporta una amplia experiencia en trauma y medicina de cuidados críticos, tras servir 23 años en el Ejército de los Estados Unidos y haber publicado más de 780 artículos revisados por pares.
El Dr. Holcomb se une al Dr. Terese Hammond, recientemente nombrada experta en cuidados críticos pulmonares, fortaleciendo el liderazgo de MiNK mientras desarrolla terapias con células T asesinas naturales invariantes (iNKT) para enfermedades inmunomediadas, trastornos pulmonares y desafíos de seguridad sanitaria global. Su experiencia en medicina de trauma, activación inmunitaria y ejecución de ensayos clínicos será valiosa a medida que MiNK avanza sus programas terapéuticos hacia etapas avanzadas de desarrollo.
MiNK Therapeutics (나스닥: INKT)가 은퇴 Col. John B. Holcomb, MD, FACS를 이사회에 임명했습니다. 홀콤 박사는 트라우마 및 중환의학 분야에 방대한 전문 지식을 갖추고 있으며, 미국 육군에서 23년간 복무하고 동료 심사(peer-reviewed) 780편 이상을 저술했습니다.
홀콤 박사는 최근 임명된 폐중환 트라우마 전문의 Terese Hammond 박사와 함께 MiNK의 리더십을 강화하고 있으며, 면역 매개 질환, 폐 질환, 글로벌 보건 안보 과제를 다루는 불변자연살해 T세포(iNKT) 치료 개발을 추진하고 있습니다. 트라우마 의학, 면역 활성화, 임상시험 수행에 대한 그의 전문성은 MiNK의 치료 프로그램이 후기 개발 단계로 진입하는 데 큰 도움이 될 것입니다.
MiNK Therapeutics (Nasdaq: INKT) a nommé au conseil d’administration le colonel à la retraite John B. Holcomb, MD, FACS. Le Dr Holcomb apporte une expertise approfondie en traumatologie et en médecine des soins intensifs, après 23 ans de service dans l’armée américaine et plus de 780 publications évaluées par des pairs.
Le Dr Holcomb rejoint le Dr Terese Hammond, récemment nommée experte en soins critiques pulmonaires, renforçant le leadership de MiNK alors que l’entreprise développe des thérapies par cellules T NK invariantes (iNKT) pour les maladies immunomédiées, les troubles pulmonaires et les défis de sécurité sanitaire mondiaux. Son expertise en médecine traumatique, activation immunitaire et exécution d’essais cliniques sera précieuse alors que MiNK fait progresser ses programmes thérapeutiques vers le développement en phase avancée.
MiNK Therapeutics (Nasdaq: INKT) hat den pensionierten Oberst John B. Holcomb, MD, FACS in den Vorstand berufen. Dr. Holcomb bringt umfassende Expertise in Trauma- und Intensivmedizin mit, nachdem er 23 Jahre in der US-Armee diente und mehr als 780 peer-reviewed Publikationen verfasst hat.
Dr. Holcomb tritt neben den kürzlich ernannten pneumonologisch-intensivmedizinischen Experten Dr. Terese Hammond hinzu und stärkt MiNKs Führung, während das Unternehmen invariant natürliche Killer-T (iNKT) Zelltherapien für immunvermittelte Erkrankungen, Lungenerkrankungen und globale Gesundheitsherausforderungen entwickelt. Seine Kompetenz in Traumatologie, Immunaktivierung und Durchführung klinischer Studien wird von Nutzen sein, während MiNK seine therapeutischen Programme in die späte Entwicklungsphase überführt.
MiNK Therapeutics (ناسداك: INKT) عيّنت الكولونيل المتقاعد جون بي. هولكوم، MD، FACS في مجلس إدارتها. يجلب الدكتور هولكوم خبرة واسعة في الطب العاجل والاصابات، وقد خدم 23 عامًا في الجيش الأمريكي وألف أكثر من 780 منشورًا في مراجعات النظراء.
ينضم الدكتور هولكوم إلى جانب الخبير في طب الرئة والاعتلالات الحرجة الجديد الدكتور تيريس هاموند، مما يعزز قيادة MiNK بينما تطور علاجات خلايا T قاتلة طبيعيةInvariant (iNKT) للأمراض المناعية واعتلالات الرئة وتحديات الأمن الصحي العالمي. ستستفيد MiNK من خبرته في الطب الصدماتي، وتنشيط المناعة، وتنفيذ التجارب السريرية وهو يقود البرامج العلاجية نحو التطوير المتقدم.
MiNK Therapeutics (纳斯达克：INKT) 已任命退役上校 John B. Holcomb, MD, FACS 为董事会成员。Holcomb 博士在创伤与重症医学领域拥有丰富的专业知识，曾在美军服役23年，并发表了超过780篇同行评审论文。
Holcomb 博士将加入最近任命的肺部重症护理专家 Terese Hammond 博士之列，巩固 MiNK 的领导地位，开发用于免疫介导疾病、肺部疾病以及全球健康安全挑战的 不变量自然杀伤T细胞治疗（iNKT）。他在创伤医学、免疫激活和临床试验执行方面的专长，将为 MiNK 将治疗项目推进到后期开发阶段提供重要支持。
- Appointment of highly qualified board member with over 780 peer-reviewed publications
- Strategic alignment with company's focus on immune-mediated diseases and pulmonary disorders
- Strengthened leadership expertise in clinical trial execution and healthcare systems
- None.
Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors.
Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocols. Post-military, he has continued to drive impact in academic medicine and biotech, with more than 780 peer-reviewed publications, multiple board memberships, and leadership in prehospital blood transfusion programs.
Dr. Holcomb’s appointment comes at a time when Americans face escalating challenges from cancer, rising rates of pulmonary disease, multidrug-resistant infections, and the persistent threat of emerging pandemics. He joins MiNK alongside recently appointed pulmonary critical care expert Dr. Terese Hammond, reinforcing MiNK’s commitment to tackling diseases of profound epidemiologic burden where both patient lives and public health security are at stake.
“We are honored to welcome Dr. Holcomb to the MiNK Board at this transformative stage in our company’s journey,” said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. “John’s unmatched expertise in trauma and surgical critical care medicine, immune activation, and clinical trial execution brings MiNK precisely the kind of insight needed as we advance iNKT cell therapies into late-stage development. His deep experience in building systems of care — from the battlefield to the ICU — and his leadership across global health networks will help us design and deliver programs that address the most pressing challenges. John’s perspective will be instrumental in guiding MiNK toward its next phase of growth, preparedness, and impact.”
“MiNK is advancing iNKT cell therapies with the potential to change how we treat interrelated immune-driven diseases seen on the battlefield and in our acute care hospitals — from trauma and ARDS to multi drug-resistant infections. This unique cellular therapy offers a new approach where current therapies have fallen short, addressing conditions that share common pathways of immune dysregulation. I am eager to help guide MiNK as it brings these breakthroughs closer to patients and strengthens our national preparedness for impending health crises,” said Dr Holcomb.
Dr. Holcomb’s appointment reinforces MiNK’s commitment to clinical rigor and operational excellence as the company continues to scale its therapeutic pipeline and global footprint.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit https://minktherapeutics.com or follow us on X @MiNK_iNKT.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, anticipated benefit, development plans, and future potential of iNKT cells and CAR-iNKT therapies. These forward-looking statements are subject to risks and uncertainties, including those described under the “Risk Factors” section of MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f6b65d62-92c7-4443-857c-899a56f8c982
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
Who is Dr. John B. Holcomb and why did MiNK Therapeutics (INKT) appoint him?
What therapeutic areas is MiNK Therapeutics (INKT) focusing on?
What is Dr. Holcomb's experience in medical research?
How will Dr. Holcomb's appointment benefit MiNK Therapeutics?
